摘要
目的对比替格瑞洛与氯吡格雷治疗急性冠状动脉综合征患者的临床疗效。方法选取2016年1月至2017年6月我院收治的60例急性冠状动脉综合征患者,采用随机数字表法进行分组,对照组患者采用氯吡格雷治疗,研究组患者采用替格瑞洛治疗。比较两组患者的治疗效果、血液学指标(血小板计数、血小板聚集率)、炎症指标(肿瘤坏死因子-α、白细胞介素-6)以及不良反应发生情况。结果研究组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。研究组血小板计数、血小板聚集率优于对照组,差异有统计学意义(P<0.05)。研究组肿瘤坏死因子-α、白细胞介素-6优于对照组,差异有统计学意义(P<0.05)。研究组不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论对急性冠状动脉综合征患者实施替格瑞洛治疗的效果优于采用替格瑞洛治疗的患者,可更好改善患者的血清学指标,促使患者机体的炎症显著下降,从而加速患者病情的康复。
Objective To compare the clinical efficacy of ticagrelor and clopidogrel in the treatment of patients with acute coronary syndrome.Methods Sixty patients with acute coronary syndrome admitted to our hospital from January 2016 to June 2017 were selected and grouped by random number table.The control group was treated with clopidogrel and the study group was treated with ticagrelor.The treatment effects,hematological indicators(platelet count,platelet aggregation rate),inflammatory indicators(tumor necrosis factor-α,interleukin-6)and the occurrence of adverse reactions were compared between the two groups of patients.Results The total effective rate of treatment in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).The platelet count and platelet aggregation rate of the study group were better than those of the control group,and the difference was statistically significant(P<0.05).Tumor necrosis factor-αand interleukin-6 in the study group were better than those in the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The effect of ticagrelor treatment on patients with acute coronary syndrome is better than that of patients treated with ticagrelor,which can better improve the patient's serological indicators,promote a significant decrease in the patient’s body inflammation,and accelerate the patient’s recovery.
作者
梁多才
LIANG Duocai(The Third People's Hospital of Benxi County,Benxi 117104,China)
出处
《中国医药指南》
2020年第35期137-138,141,共3页
Guide of China Medicine